Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019
Q1 FY19 results · Apr–Jun 2018
Jubilant Pharmova reported revenue from operations of ₹2,078.65 crore and net profit of ₹200.37 crore for Q1 FY19 (Apr–Jun 2018), on a consolidated basis.
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,078.65 | — | — | — | — |
| Other income | 9.47 | — | — | — | — |
| Total income | 2,088.12 | — | — | — | — |
| Profit before tax | 286.37 | — | — | — | — |
| Net profit for the period | 200.37 | — | — | — | — |
| Attributable to shareholders of the company | 202.50 | — | — | — | — |
| EPS, basic (₹) | 13.00 | — | — | — | — |
| Net margin (%) | 9.6 | — | — |
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 826.64 | — | — | — | — |
| Other income | 4.41 | — | — | — | — |
| Total income | 831.05 | — | — | — | — |
| Profit before tax | 33.45 | — | — | — | — |
| Net profit for the period | 23.88 | — | — | — | — |
| EPS, basic (₹) | 1.50 | — | — | — | — |
| Net margin (%) | 2.9 | — | — |
Consolidated
- Filed with BSE
- 30 Jul 2018, 11:09 IST
- Board meeting
- 27 Jul 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jul 2018, 11:09 IST
- Board meeting
- 27 Jul 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE